Five of these antigens (VPS35, ARPC2, SERBP1, KRT8, and PDIA6) were selected because they inhibited human breast cancer survival across two aggressive breast cancer subtype cell lines (HER2 positive and triple negative). This evidence concerns the gene ARPC2 and breast cancer.